




STATE MEDICAID P&T COMMITTEE MEETING
THURSDAY, February 16, 2012
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 114



MINUTES

Committee Members Present:

Ellie Brownstein, M.D.
Lisa Hunt, R.Ph.
Beth Johnson, R.Ph.
Julia Ozbolt, M.D.

Kort DeLost, R.Ph.
Jameson Rice, Pharm.D.
Bernadette Kiraly, M.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Tim Morley, R.Ph.
Richard Sorenson, R.N.

Bobbi Hansen, CPhT.
Robyn Seely, Pharm.D.

University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Gary Oderda, Pharm.D.

Other Individuals Present:

Kim Eggert, Gilead
Antoinette Brown, GHS

Charissa Anne, J&J
Mike Ouellette, GHS

Meeting conducted by: Ellie Brownstein.

- 1 Review and Approval of Minutes: Kort Delost moved to approve the minutes. Ellie Brownstein seconded the motion. The motion was approved unanimously.
- 2 Housekeeping: Lisa Hunt reported that an updated PDL is now posted, the updated PDL features and new format with columns identifying preferred, non-preferred and comments section.

Utah Medicaid's new point-of-sale system is going live February 20th.

Accountable Care Organizations (ACOs) are coming to Utah Medicaid with a projected implementation date of October 2012 (at the very soonest).
- 3 Drug Utilization Review (DUR) Board update: DUR board reviewed Zaralto, will require a clinical prior authorization. They also reviewed Brilinta, will be available without prior authorization.
- 4 **Anti-Virals for Influenza:** Melissa Archer provided an overview of the anti-virals for influenza.

Ellie Brownstein commented that the timeframe associated with obtaining a prior authorization for Tamiflu slows the effectiveness. Beth Johnson agreed that clinically, no prior authorization makes sense. Robyn Seely pointed out that Medicaid is required to respond to all prior authorization requests within 24 hours. Additionally, if a client is attempting to fill a medication when Medicaid is unavailable (weekend/holiday) the medication is automatically covered for a 72 hour supply.

Bernadette Kiraly asked if they could look at a copy of the Tamiflu prior authorization criteria sheet. A sheet was provided for each committee member. Lisa Hunt affirmed that the criteria determination is handled by the DUR board, and reminded the committee that they can make a recommendation for the DUR board to re-review prior authorization criteria.

Julia Ozbolt suggested that there is a lot of utilization of Amantadine in treatment of Parkinson's.

Public Comment: none

Other States: Lisa Hunt provided data from other states PDLs for consideration.

Board Actions: Ellie Brownstein made a motion that a recommendation be made to the DUR board to reconsider the prior authorization criteria for Tamiflu. Beth Johnson seconded the motion. The motion was approved unanimously.

Ellie Brownstein made a motion that the presented drugs appear to be equally safe and efficacious. Julia Ozbolt seconded the motion. The motion was approved unanimously.

Kort Delost made a motion to include Amantadine in the Parkinson's agents class and include Tamiflu in the Anti-virals (Influenza) class. Bernadette Kiraly seconded the motion. The motion was approved unanimously.

- 5 **Oral Anti-virals for HSV and CMV:** Melissa Archer provided an overview of the oral anti-virals for HSV and CMV. The University of Utah recommends coverage of at least one of Acyclovir, Famciclovir, Valacyclovir and/or Valganciclovir for CMV.

The utilization data presented showed pediatric usage. Bernadette Kiraly suggested coverage of a suspension for the pediatric population.

Public Comment: none

Other States: Lisa Hunt provided data from other states PDLs for consideration.

Board Actions: Ellie Brownstein made a motion that the agents presented for treatment of CMV appear to be equally safe and efficacious. Beth Johnson seconded the motion. The motion was approved unanimously.

Ellie Brownstein made a motion to cover at least one of Valacyclovir or Valganciclovir. Beth Johnson seconded the motion. The motion was approved unanimously.

Ellie Brownstein made a motion that the agents presented for treatment of HSV appear to be equally safe and efficacious. Beth Johnson seconded the motion. The motion was approved unanimously.

Ellie Brownstein made a motion to cover both a solid and liquid dosage form of Acyclovir. Bernadette Kiraly seconded the motion. The motion was approved unanimously.

Next Meeting Set for Thursday, March 15, 2012 – H2 Antagonists

Meeting Adjourned.

Minutes prepared by Bobbi Hansen. – No Recording available.